|
Characteristic
|
Selinexor 60 mg QW/BIW + carboplatin 6 AUC Q3W (N = 6)
|
Selinexor 60 mg QW/BIW + doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 Q3W (N = 4)
|
Selinexor 40 mg QW + FOLFIRIa (N = 3)
|
Selinexor 60 mg QW + irinotecan 125 mg/m2 D1 and 8 Q3W (N = 3)
|
Selinexor 40 mg QW + XELOXb (N = 3)
|
All patients (N = 19)
|
|---|
|
Age at consent (years)
|
|
Median range
|
56.1 (31.2–76.1)
|
61.7 (23.6–64.9)
|
49.9 (38.1–70.7)
|
67.8 (57.9–72.3)
|
65.9 (51.8–72.8)
|
60.6 (23.6–76.1)
|
|
Gender, N (%)
|
|
Male
|
1 (17)
|
2 (50)
|
1 (33)
|
1 (33)
|
2 (67)
|
7 (37)
|
|
Female
|
5 (83)
|
2 (50)
|
2 (67)
|
2 (67)
|
1 (33)
|
12 (63)
|
|
Race/ethnicity, N (%)
|
|
White
|
4 (67)
|
4 (100)
|
3 (100)
|
1 (33)
|
3 (100)
|
15 (79)
|
|
Hispanic
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Black
|
1 (17)
|
0
|
0
|
1 (33)
|
0
|
2 (11)
|
|
Asian
|
1 (17)
|
0
|
0
|
1 (33)
|
0
|
2 (11)
|
|
ECOG performance status, N (%)
|
|
0
|
1 (17)
|
0
|
1 (33)
|
2 (67)
|
1 (33)
|
5 (26)
|
|
1
|
5 (83)
|
4 (100)
|
2 (67)
|
1 (33)
|
2 (67)
|
14 (74)
|
|
Primary tumor, N (%)
|
|
Ovarian
|
0
|
2 (50)
|
0
|
0
|
0
|
2 (11)
|
|
Breast
|
3 (50)
|
0
|
0
|
0
|
0
|
3 (16)
|
|
Colorectal cancer
|
0
|
0
|
1 (33)
|
1 (33)
|
1 (33)
|
3 (16)
|
|
Endometrial/fallopian
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Lung
|
1 (17)
|
0
|
0
|
0
|
0
|
1 (5)
|
|
Neuroendocrine
|
0
|
0
|
1 (33)
|
1 (33)
|
0
|
2 (11)
|
|
Pancreas
|
0
|
0
|
1 (33)
|
0
|
1 (33)
|
2 (11)
|
|
Esophageal
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Head and neck/salivary gland
|
1 (17)
|
0
|
0
|
1 (33)
|
0
|
2 (11)
|
|
Liver/cholangiocarcinoma
|
0
|
0
|
0
|
0
|
1 (33)
|
1 (5)
|
|
Sarcoma
|
0
|
1 (25)
|
0
|
0
|
0
|
1 (5)
|
|
Prostate
|
0
|
1 (25)
|
0
|
0
|
0
|
1 (5)
|
|
Others
|
1 (17)
|
0
|
0
|
0
|
0
|
1 (5)
|
|
Prior lines of systemic therapies, N (%)
|
|
0–1
|
1 (17)
|
0
|
0
|
0
|
0
|
1 (5)
|
|
2–3
|
4 (67)
|
3 (75)
|
2 (67)
|
2 (67)
|
2 (67)
|
13 (68)
|
|
4–5
|
1 (17)
|
1 (25)
|
1 (33)
|
0
|
1 (33)
|
4 (21)
|
|
> 5
|
0
|
0
|
0
|
1 (33)
|
0
|
1 (5)
|
|
Median range
|
2.5 (1.0–4.0)
|
2.0 (2.0–4.0)
|
3.0 (3.0–5.0)
|
3.0 (2.0–6.0)
|
3.0 (2.0–4.0)
|
3.0 (1.0–6.0)
|
- N number; ECOG Eastern Cooperative Oncology Group; QW once weekly; BIW twice weekly; AUC area under curve; mg/m2 milligrams per square meter; D1 and 8 on days 1, and 8 of each cycle; Q3W every 3 week; FOLFIRI irinotecan with fluorouracil and folinic acid; XELOX capecitabine and oxaliplatin
- aFOLFIRI—irinotecan of 180 mg/m2, 5-FU continuous infusion of 2400 mg/m2, 5-FU bolus of 400 mg/m2, and leucovorin of 400 mg/m2 on days 1, and 15
- bXELOX—capecitabine was dosed at 900 mg/m2 orally (PO) divided into 2 doses on days 1–14, along with oxaliplatin of 130 mg/m2 IV Q3W
